These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7592188)

  • 1. Lipid-based formulations of amphotericin B.
    Swenson CE; Bolcsak LE; Perkins WR; Janoff AS
    J Antimicrob Chemother; 1995 May; 35(5):709-13. PubMed ID: 7592188
    [No Abstract]   [Full Text] [Related]  

  • 2. Amphotericin B formulated in a lipid emulsion.
    Cleary JD
    Ann Pharmacother; 1996 Apr; 30(4):409-12. PubMed ID: 8729899
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.
    Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM
    Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Sievers TM; Kubak BM; Wong-Beringer A
    J Antimicrob Chemother; 1996 Sep; 38(3):333-47. PubMed ID: 8889711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results].
    Blancard A; Monges P; Lacarelle B; Denis JP; Bongrand MC; Ragon CH; Gouin F
    Pathol Biol (Paris); 1996 May; 44(5):384-8. PubMed ID: 8758481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B does not mix with fat emulsion.
    Trissel LA
    Am J Health Syst Pharm; 1995 Jul; 52(13):1463-4. PubMed ID: 7671046
    [No Abstract]   [Full Text] [Related]  

  • 7. Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion.
    Owens D; Fleming RA; Restino MS; Cruz JM; Hurd DD
    Am J Health Syst Pharm; 1997 Mar; 54(6):683-6. PubMed ID: 9075499
    [No Abstract]   [Full Text] [Related]  

  • 8. Amphotericin B intralipid formulation: stability and particle size.
    Ranchère JY; Latour JF; Fuhrmann C; Lagallarde C; Loreuil F
    J Antimicrob Chemother; 1996 Jun; 37(6):1165-9. PubMed ID: 8836819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar.
    Thakur CP
    Trans R Soc Trop Med Hyg; 1994; 88(6):698-9. PubMed ID: 7886778
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment: compatibility of amphotericin B with lipid emulsions.
    Montoro JB; López RM; Pou L
    Ann Pharmacother; 1996 Dec; 30(12):1501. PubMed ID: 8968472
    [No Abstract]   [Full Text] [Related]  

  • 11. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion.
    Lopez RM; Ayestaran A; Pou L; Montoro JB; Hernandez M; Caragol I
    Am J Health Syst Pharm; 1996 Nov; 53(22):2724-7. PubMed ID: 8931814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical formulations of amphotericin B].
    Tasset C; Preat V; Roland M
    J Pharm Belg; 1992; 47(6):523-36. PubMed ID: 1289493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Amphotericin B solid lipid nanoparticles: Design and development.
    Butani D; Yewale C; Misra A
    Colloids Surf B Biointerfaces; 2016 Mar; 139():17-24. PubMed ID: 26700229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precipitation of amphotericin B from i.v. fat emulsion.
    Heide PE
    Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid formulations of amphotericin B: recent progress and future directions.
    Hiemenz JW; Walsh TJ
    Clin Infect Dis; 1996 May; 22 Suppl 2():S133-44. PubMed ID: 8722841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and toxicity of amphotericin B/triglyceride emulsion formulations.
    Lance MR; Washington C; Davis SS
    J Antimicrob Chemother; 1995 Jul; 36(1):119-28. PubMed ID: 8537259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
    Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
    J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures.
    Shadkhan Y; Segal E; Bor A; Gov Y; Rubin M; Lichtenberg D
    J Antimicrob Chemother; 1997 May; 39(5):655-8. PubMed ID: 9184368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cationic derivative of amphotericin B as a novel delivery system for antisense oligonucleotides.
    Garcia-Chaumont C; Seksek O; Jolles B; Bolard J
    Antisense Nucleic Acid Drug Dev; 2000 Jun; 10(3):177-84. PubMed ID: 10905554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical & pharmaceutical testing of liposomal amphotericin B.
    Gokhale PC; Kotwani RN; Dange SY; Kshirsagar NA; Pandya SK
    Indian J Med Res; 1993 Apr; 98():75-8. PubMed ID: 8344735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.